Available Technologies

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Find technologies available for licensing from UCSF.

Novel Drug Delivery Platform

This invention is a novel method for synthetically designing protein carriers (enFoldin) for small molecules.  

A novel method for increasing MHC presentation of oncogene derived neoantigens

The invention describes a platform technology that increases MHC presentation of oncogene derived peptide neoantigens that do not normally occur in the cell. The platform has already been used to identify a method of increasing KRAS G12 D/V derived peptide presentation on MHC- I.

Selective Covalent Inhibitors of Caspase-6

Caspase 6 (Casp6) has been implicated in several neurodegenerative conditions, including Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease. Casp6 activation has been observed during all stages of Alzheimer’s disease making it an attractive therapeutic target for neurological indications. The current invention identifies a family of covalent small molecules that selectively bind Casp6 over other caspases.

Novel microbial species that promote fetal tolerogenic immunity

New therapies to prevent the development of asthma and other chronic inflammatory diseases in infants using natural bacterial modulators of fetal immune development.

Neoantigen-specific antibodies for chemically directed immune targeting of KRAS tumors

UCSF scientists have discovered novel antibodies that can specifically and selectively recognize tumor-derived neoantigens. The antibodies can be used for IgG, BiTE or CAR-T-based targeted immunotherapy and small molecule-based directed immune targeting via combination therapy. This dual therapeutic approach has the potential to specifically recognize and treat KRAS (G12C) cancer cell populations with high specificity, significantly improve cancer treatment outcomes, and overcome risk of treatment resistance in patients.

Fragment-Based Stabilization Of 14-3-3/Client Protein-Protein Interactions

UCSF and Technical University of Eindhoven investigators have identified molecular fragments that stabilize 14-3-3/phospho-peptide and 14-3-3/phospho-protein interactions.  Further structure-guided and empirical medicinal chemistry will lead to a drug lead for the most advanced target (estrogen receptor).   

IFN-gamma Receptor On T Cell Immunotherapy

This invention identifies that tumor-specific T cells are susceptible to immunotherapy induced IFN-gamma toxicity in low tumor burden circumstances, and provides a novel method for rescuing those tumor-reactive T cells and anti-tumor immunity through disruption of IFN-gamma signaling.